ASND - Ascendis Pharma AS

Momentum: Bearish

Recent News

Are Medical Stocks Lagging Ascendis Pharma ( ASND ) This Year?

Zacks Commentary • 4 months, 4 weeks ago • score: 0.24

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.

52W High

$207.00

52W Low

$111.09

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.39

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

45.25

EV/EBITDA (<8 favorable)

-20.75

EV/Revenue (<3 favorable)

22.40

P/S (TTM) (<3 favorable)

25.41

P/B (<3 favorable)

14.55

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.78%

Institutions (25–75% balanced)

106.99%

Shares Outstanding

60,554,000

Float

60,083,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

490,747,000

Gross Profit (TTM)

416,560,000

EPS (TTM)

-5.29

Profit Margin (>10% good)

-0.55%

Operating Margin (TTM) (higher better)

-0.34%

ROE (TTM) (>15% strong)

-8.18%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

3.39

Momentum

Bearish momentum

Value

5.1299

5.7558

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025